Heather D Nelkin

Dr. Heather D Nelkin

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2025 in Mental Health Clinician
Verified
Journal Article
Open access
EBEric Borrelli
Eric Borrelli
MTMonica Telinoiu
Monica Telinoiu
PSPeter Saad
Peter Saad
NBNathan Barnes
Nathan Barnes
HNHeather D Nelkin
Heather D Nelkin
JLJulia Lucaci
Julia Lucaci
Introduction: Medication nonadherence is a prevalent and significant public health issue in the United States, particularly among patients with psychiatric disorders. Blister packaging medications is one of the most widely recognized and validated strategies for enhancing medication adherence. Given the paramount importance of adherence in psychiatry and the demonstrated effectiveness of blister packaging in chronic disorders, it is imperative to evaluate its effect in this context. Methods: A systematic literature review was conducted in PubMed and Google Scholar in May 2024 to identify relevant studies assessing the effect of blister packaging on medication adherence, health outcomes, and health care costs in psychiatry. Studies were included if they provided quantitative data on the effects of blister packaging on medication adherence in psychiatry. A meta-analysis was not performed due to differences in definitions of adherence in the included studies. Results: The review included 3 clinical studies and 1 cost-utility analysis (CUA). All 3 clinical studies demonstrated that blister packaging improved medication adherence rates. However, minimal data was available regarding its effect on clinical or patient-reported outcomes. The CUA found that blister packaging was dominant (less costly and more effective) compared with standard vial packaging. Discussion: The evidence presented in this review substantiates the positive effect for blister packaging in a psychiatric population. Nevertheless, due to the limited scope and size of the studies reviewed, further research with larger sample sizes is needed to fully assess the broader effect of blister packaging on clinical outcomes and health care costs within psychiatry.

5 June 2024 in Journal of the American Pharmacists Association
Verified
Journal Article
Closed access
EBEric Borrelli
Eric Borrelli
MTMonica Telinoiu
Monica Telinoiu
HNHeather D Nelkin
Heather D Nelkin
DDDoina Dumitru
Doina Dumitru
JLJulia D. Lucaci
Julia D. Lucaci

4 December 2024 in Pharmacy
Verified
Journal Article
Open access
PDF file
SBSamantha Shannon Bastow
Samantha Shannon Bastow
EBEric Borrelli
Eric Borrelli
JLJulia Lucaci
Julia Lucaci
HNHeather D Nelkin
Heather D Nelkin
AGApril Graves
April Graves
AHAmanda Hays
Amanda Hays
This study explored controlled substance (CS) diversion surveillance practices within hospital pharmacies across the United States. A survey with questions based on published CS diversion risk points was conducted in May 2024. A total of 66 participants from 31 states responded, with 54.5% from single facilities and the remaining from health systems. Most respondents were pharmacy directors, managers, or those in dedicated drug diversion roles. Over 70% have dedicated surveillance teams and use drug diversion software. Results highlight variation in practices, with larger institutions generally showing better compliance. Compliance in procurement and receiving was high for access measures; however, auditing of processes was lower. The lowest procurement compliance was in monitoring periodic automatic replacement (PAR) levels and validating orders with wholesalers. Storage practices showed high compliance in deploying cameras, but low compliance in monitoring them. Dispensing practices had high compliance for restricting CS in automated dispensing cabinets, but low incidence of witness verification during stocking. Waste and disposal practices were well-followed, but training on detecting potential signs of medication tampering was less common. The survey highlights that while strategies to prevent CS diversion exist, their implementation varies. Enhancing monitoring, auditing, and training is essential to strengthen diversion prevention efforts in hospital pharmacies.

1 October 2024 in Substance Abuse and Rehabilitation
Verified
Journal Article
Open access
PDF file
EBEric Borrelli
Eric Borrelli
PSPeter Saad
Peter Saad
NBNathan Barnes
Nathan Barnes
HNHeather D Nelkin
Heather D Nelkin
DDDoina Dumitru
Doina Dumitru
JLJulia Lucaci
Julia Lucaci
Background: The opioid epidemic has severely impacted the US over the last 15 years. Buprenorphine is a partial opioid agonist indicated for the treatment of opioid use disorder (OUD) and is recognized as an effective treatment when taken as prescribed. However, adherence rates have been low in real-world settings. Blister-packaging has been shown to promote medication adherence across a variety of disease states, although it has never been studied in OUD. Methods: An economic analysis was conducted to assess the impact of increased adherence of blister-packaged buprenorphine on health care resource utilization (HCRU) and health care costs for 10,000 patients initiating therapy for OUD. The model analyzed a commercially insured population within the US over a one-year time horizon. Medication adherence was defined in the model as proportion of days covered (PDC) of at least 80%. Literature-based references were used to inform both the impact of blister-packaging on the number of patients who became adherent as well as the impact of medication adherence on HCRU and health care costs. Model input uncertainty was assessed in one-way sensitivity analyses. Results: With the implementation of blister-packaging buprenorphine, adherence rates increased from 37.1% of patients in the pre-intervention period to 45.3%, resulting in an additional 818 patients becoming adherent post-intervention. The increase in adherence led to a reduction of medical costs of $12,138,757 (-$1,214 per-patient (PP)). Specifically, inpatient costs decreased by $7,127,073 (-$713 PP) while outpatient costs decreased by $5,013,319 (-$501 PP). Pharmacy costs increased by $3,432,705 ($343 PP). Despite the increase in pharmacy costs, total health care costs saw a reduction of $8,559,684 (-$856 PP). Conclusion: Blister-packaging buprenorphine for treatment of OUD has potential to improve medication adherence and health outcomes while reducing HCRU and health care costs. Future studies are necessary to assess the real-world application and impact of blister-packaging buprenorphine for OUD across various patient populations and health care settings. Plain Language Summary: The opioid epidemic has taken its toll in the United States for the last several decades. Several medications are available in the treatment of opioid use disorder (OUD), including buprenorphine. Buprenorphine has shown to be an effective treatment when taken as prescribed, however, in real-world settings, the occurrence of patients taking buprenorphine as prescribed is low. Blister-packaging medications has been shown to help promote medication adherence across a variety of disease states, although it has never been studied in OUD. As a result, we attempted to model the potential impact that blister-packaging buprenorphine for 10,000 commercially insured patients initiating treatment for OUD would have on health care resource utilization and health care costs using the best available peer-reviewed literature. This analysis saw adherence rates increased from 37.1% of patients in the pre-blister-packaging period to 45.3% post-blister-packaging period, resulting in an additional 818 patients becoming adherent. The increase in adherence led to reductions of medical costs of $12,138,757 (-$1214 per-patient (PP)). Specifically, inpatient costs decreased by $7,127,073 (-$713 PP) while outpatient costs decreased by $5,013,319 (-$501 PP). Pharmacy costs increased by $3,432,705 ($343 PP). Despite the increase in pharmacy costs, total health care costs saw a reduction of $8,559,684 (-$856 PP). Future studies are necessary to assess the real-world application and impact of blister-packaging buprenorphine for OUD across various patient populations and health care settings.

30 August 2025 in Journal of the American Pharmacists Association
Verified
Journal Article
Open access
EBEric Borrelli
Eric Borrelli
NBNathan E. Barnes
Nathan E. Barnes
PSPeter Saad
Peter Saad
KDKristie Dooley
Kristie Dooley
HNHeather D Nelkin
Heather D Nelkin
JLJulia Lucaci
Julia Lucaci
The Medicare Star Ratings program, administered by the Centers for Medicare & Medicaid Services, includes a list of quality measures aimed at evaluating the quality of care provided by Medicare health plans. These measures include three medication adherence measures (non-insulin antidiabetics, renin-angiotensin system antagonists (RASA), and statins), as well as a plan all-cause readmission (PACR) measure, among dozens of other measures. To examine the potential association between the three Medicare Star Rating medication adherence measures and the PACR measure. An analysis of the publicly available annual health plan Medicare Star Rating performance data was conducted for the Star Rating years of 2015-2024, except years 2021-2023 where the PACR measure was not assessed. The primary outcomes were odds ratios (OR) and 95% confidence intervals (CI) evaluating the likelihood of a health plan achieving ≥4-stars on the PACR measure if it also earned ≥4-stars or 5-stars on the adherence measure(s). Health plans that achieved ≥4-stars or 5-stars on the RASA measure had significantly higher odds of achieving ≥4-stars on the PACR measure (OR:1.53, 95% CI:1.30-1.81; OR:1.51, 95% CI:1.26-1.81; respectively), as did plans that achieved ≥4-stars or 5-stars on the statin adherence measure (OR:1.58, 95% CI:1.31-1.86; OR:1.94, 95% CI:1.55-2.43; respectively). There was no significant impact for the diabetes adherence measure (≥4-stars OR:1.10, 95% CI:0.93-1.30; 5-stars OR:1.09, 95% CI:0.89-1.33). The likelihood of achieving ≥4-stars on the PACR measure increased non-significantly with the number of adherence measures that achieved 5-stars (all 3 adherence measures OR:1.53, 95% CI:1.17-2.00; only 2 adherence measures OR:1.44, 95% CI:1.09-1.90; only 1 adherence measure OR:1.11, 95% CI:0.87-1.41). Health plans with higher performance on the Medicare Star Ratings adherence measures had significantly increased odds of high performance on the Medicare Star Ratings PACR measure, suggesting an association between effective medication management and reduced all-cause readmissions.

18 August 2026 in Journal of Pharmacy Practice
Verified
Journal Article
Closed access
JPJacqueline Pham
Jacqueline Pham
WTWyndie Tse
Wyndie Tse
TNTiffany Nguyen
Tiffany Nguyen
CGCraig A. Greszler
Craig A. Greszler
HNHeather D Nelkin
Heather D Nelkin
Automated dispensing cabinet (ADC) overrides facilitate timely medication access but bypass standard medication-use safety checks, necessitating ongoing monitoring to identify potential risks. Many health systems rely on manual, retrospective workflows to review override activity, yet operational burden associated with these processes is not well characterized. Objectives of the evaluation were to describe the workflow, quantify the time burden, and identify limitations associated with a manual ADC override monitoring process within a large health system. This retrospective, descriptive quality improvement evaluation was conducted at a large oncology-focused health system. The existing ADC override review process was assessed over a 6-month period. Workflow steps included generation of external reports, manual alignment and manipulation of data within spreadsheets, and creation of pivot table summaries for analysis across patient care areas. Time required to complete each monthly override audit was tracked, and process limitations were documented. The mean time required to complete a monthly override audit was 1 h and 7 min, with a range of 42 min to 1 h and 55 min. The most time-intensive activities were spreadsheet construction, data manipulation, and report preparation. Additional effort was required to train and validate reviewers. Key process limitations included reliance on retrospective reporting, lack of standardized review methodologies, and challenges aggregating data to identify system-level trends. Manual ADC override monitoring is resource intensive and subject to variability due to retrospective, spreadsheet-based workflows. These findings suggest a need for optimized and standardized approaches to support medication safety surveillance and improve scalability of override review processes.